A compound originally developed to treat cancer could be repurposed to treat polycystic kidney disease, an inherited condition that can lead to kidney failure.

MIT CSAIL researchers develop advanced machine-learning models that outperform current methods in detecting pancreatic ductal adenocarcinoma.

The advance makes it easier to detect circulating tumor DNA in blood samples, which could enable earlier cancer diagnosis and help guide treatment.

The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.

By reevaluating existing data, researchers find the procedure is even more valuable than consensus had indicated.

MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.

The wearable device, designed to monitor bladder and kidney health, could be adapted for earlier diagnosis of cancers deep within the body.

Thirteen new graduate student fellows will pursue exciting new paths of knowledge and discovery.

The findings could help doctors identify cancer patients who would benefit the most from drugs called checkpoint blockade inhibitors.

The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.